MA30086B1 - Derives de 3-alkylazetidine a substituants heterocycliques. - Google Patents

Derives de 3-alkylazetidine a substituants heterocycliques.

Info

Publication number
MA30086B1
MA30086B1 MA31075A MA31075A MA30086B1 MA 30086 B1 MA30086 B1 MA 30086B1 MA 31075 A MA31075 A MA 31075A MA 31075 A MA31075 A MA 31075A MA 30086 B1 MA30086 B1 MA 30086B1
Authority
MA
Morocco
Prior art keywords
treatment
disorders
useful
compounds
disease
Prior art date
Application number
MA31075A
Other languages
English (en)
French (fr)
Inventor
Robert K Baker
Jeffrey J Hale
Shouwu Miao
Kathleen M Rupprecht
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA30086B1 publication Critical patent/MA30086B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA31075A 2005-11-28 2008-06-25 Derives de 3-alkylazetidine a substituants heterocycliques. MA30086B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74018305P 2005-11-28 2005-11-28

Publications (1)

Publication Number Publication Date
MA30086B1 true MA30086B1 (fr) 2008-12-01

Family

ID=37779312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31075A MA30086B1 (fr) 2005-11-28 2008-06-25 Derives de 3-alkylazetidine a substituants heterocycliques.

Country Status (15)

Country Link
EP (1) EP1954692A1 (ko)
KR (1) KR20080073721A (ko)
AR (1) AR058199A1 (ko)
BR (1) BRPI0619018A2 (ko)
CR (1) CR10014A (ko)
DO (1) DOP2006000261A (ko)
EC (1) ECSP088477A (ko)
IL (1) IL191586A0 (ko)
MA (1) MA30086B1 (ko)
NO (1) NO20082919L (ko)
PE (1) PE20070647A1 (ko)
RU (1) RU2008126248A (ko)
SV (1) SV2009002917A (ko)
TW (1) TW200804317A (ko)
WO (1) WO2007062193A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906652B2 (en) * 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009054923A2 (en) * 2007-10-24 2009-04-30 Merck & Co., Inc. Synthesis and crystalline forms of cb-1 antagonist/inverse agonist
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
US7485732B2 (en) * 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
CN101426500A (zh) * 2005-05-02 2009-05-06 默克公司 治疗糖尿病和肥胖症的二肽基肽酶iv抑制剂和cb1受体拮抗剂的药物组合物

Also Published As

Publication number Publication date
RU2008126248A (ru) 2010-01-10
BRPI0619018A2 (pt) 2016-11-29
PE20070647A1 (es) 2007-08-11
EP1954692A1 (en) 2008-08-13
DOP2006000261A (es) 2007-07-15
ECSP088477A (es) 2008-06-30
CR10014A (es) 2008-07-29
TW200804317A (en) 2008-01-16
NO20082919L (no) 2008-08-27
IL191586A0 (en) 2008-12-29
WO2007062193A1 (en) 2007-05-31
KR20080073721A (ko) 2008-08-11
SV2009002917A (es) 2009-02-19
AR058199A1 (es) 2008-01-23

Similar Documents

Publication Publication Date Title
MA27847A1 (fr) Derives d'azetidine substituee avec 3-alkyle et 3-alcenyle.
MA30086B1 (fr) Derives de 3-alkylazetidine a substituants heterocycliques.
DE60334787D1 (de) Substituierte amide
MY134457A (en) Substituted amides
DE60316829D1 (de) Substituierte furoä2,3-büpyridin derivate
WO2003086288A3 (en) Bicyclic amides
WO2004058145A3 (en) Substituted amides
WO2004029204A3 (en) Substituted pyrimidines
ATE452890T1 (de) Substituierte naphthyridinonderivate
WO2003082190A3 (en) Spirocyclic amides as cannabinoid receptor modulators
WO2003063781A3 (en) Substituted imidazoles as cannabinoid receptor modulators
WO2003082191A3 (en) Substituted 2,3-diphenyl pyridines
WO2003007887A3 (en) Substituted imidazoles as cannabinoid receptor modulators
WO2005027837A3 (en) Substituted sulfonamides
WO2008024284A3 (en) Sulfonylated piperazines as cannabinoid-1 receptor modulators
DE602008005405D1 (de) Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren
WO2007064566A3 (en) Heterocycle-substituted 3-alkyl azetidine derivatives
US20190389865A1 (en) SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
MX2007007472A (es) Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c.
DE602004024188D1 (de) Des opioid-rezeptors
ATE457985T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
WO2006041797A3 (en) Acyclic hydrazides as cannabinoid receptor modulators
CA2522323A1 (en) 3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands
DE602006013040D1 (de) Substituierte pyradinon-derivate als alpha2-adrenorezeptor-antagonisten
ATE471322T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel